Investors think mind-bending drug DMT could rival psilocybin as a cost-effective psychedelic treatment for conditions like depression. 3 VCs explain why its fast-acting properties are appealing.

July 11, 2022
May 30, 2021

Read the full story on Business Insider

Related posts